Most doses of Novo Nordisk's Ozempic are removed from FDA drug shortage list after supply issues
Novo Nordisk’s type 2 diabetes treatment Ozempic, which is also used off-label for weight loss, is back in stock following a months-long shortage, according to the FDA’s drug shortages list.
The FDA updated its website on Friday to show that Ozempic’s 0.25 mg, 0.5 mg and 1 mg doses are now available across the US. The 0.25 mg and 0.5 mg doses suffered limited supply for the last few months, according to a Novo Nordisk spokesperson. However, the 2 mg dose has “limited availability and may not fully meet demand until the end of this month,” the company told Endpoints News on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.